DUODENAL TUMOR IN GASTROINTESTINAL STROMAL TUMORS: A RARE CASE

2019 ◽  
Author(s):  
Naseem Akhtar
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
X Rays ◽  
Current Case ◽  
Her Family ◽  
Duodenal Tumor ◽  
Stromal Tumors ◽  
Scope Test ◽  
Whipple’S Procedure ◽  
Incident Rate ◽  
Tomography Scan

Gastrointestinal stromal tumors are commonly developed in gastrointestinal tract but in duodenum is less than 3% of all gastrointestinal neoplasm. The early diagnostic criteria are very difficult in these tumors in worldwide and being a challenge for medical team due to difficult anatomical structure of duodenum. The study’s aim is to know the incident rate of duodenal gastrointestinal stromal tumors. The average age of these tumors is more than 40 years but in the current case, 19-years old female patient present with complaint of melena and anemia. Her family history was negative. She was diagnosed by scope test of oral gastric duodenum with biopsy, abdominal x-rays, computerized tomography scan and histopathology. The patient was treated by Classic Whipple’s procedure. According to the oncologist, patient has low risk of duodenal tumor from gastrointestinal stromal tumor. These tumors have no need to treat with adjuvant therapy: chemotherapy (Glavic) and radiation therapy after surgical resection.

Liver metastasis from pancreatic gastrointestinal stromal tumor presenting 5 years after resection: a rare case with management challenges

2018 ◽  
pp. 1-3
Keyword(s):  
Gastrointestinal Tract ◽  
High Risk ◽  
Liver Metastasis ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Uncinate Process ◽  
Stromal Tumor ◽  
Distal Common Bile Duct ◽  
Stromal Tumors ◽  
Whipple’S Procedure

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors arising from the gastrointestinal tract. Stromal tumors arising outside the gastrointestinal tract are called extra-gastrointestinal stromal tumors, usually found in omentum, mesentery, retroperitoneum and gallbladder. We report a case of 31 years old male with 3-month history of painless jaundice and undocumented weight loss. Computerized tomography scan showed a well-defined, rounded enhancing lesion in the uncinate process of pancreas measuring 53x49mm compressing the distal common bile duct. Percutaneous biopsy confirmed gastrointestinal stromal tumor. He underwent Whipple’s procedure followed by adjuvant imatinib due to high-risk features. He remained well for a long time and developed oligo-metastasis in liver 5 years after resection while he was still on imatinib. The patient underwent hepatic resection and remains well one year after the second resection on adjuvant treatment. Pancreatic extragastrointestinal stromal tumor involving uncinate process is a rare disease entity. First line of management is negative margin resection followed by adjuvant therapy with imatinib for high-risk tumors. In case of resectable liver metastasis, resection of metastasis followed by multimodal therapy seems to prolong the disease free and overall survival.

Surgical management of gastrointestinal stromal tumors: A single institution 31 — Year experience

2001 ◽  
Vol 120 (5) ◽  
pp. A401-A401 ◽  
Author(s):  
D EFRON ◽  
K LILLEMOE ◽  
J CAMERON ◽  
S TIERNEY ◽  
S ABRAHAM ◽  
...  
Keyword(s):  
Surgical Management ◽  
Gastrointestinal Stromal Tumors ◽  
Single Institution ◽  
Stromal Tumors

Multislice imaging of gastrointestinal stromal tumors

2018 ◽  
pp. 3-14
Keyword(s):  
Computed Tomography ◽  
Key Words ◽  
Gold Standard ◽  
Gastrointestinal Stromal Tumors ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Preferential Localization ◽  
Multislice Imaging ◽  
Computed Tomography Diagnosis

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract (1%). These tumors express the CD 117 in 95% of cases. The stomach is the preferential localization (70%). Diagnosis is difficult and sometimes late. Progress of imaging has greatly improved the management and the prognosis. Computed tomography (CT) is the gold standard for diagnosis, staging, and treatment follow-up. The increasing recognition of GIST’s histopathology and the prolonged survival revealed some suggestive imaging aspects. Key words: gastro-intestinal stromal tumors; computed tomography; diagnosis

Gastrointestinal stromal tumors in neurofibromatosis type 1

2009 ◽  
Vol 150 (4) ◽  
pp. 149-153 ◽  
Author(s):  
Judit Bajor
Keyword(s):  
Neurofibromatosis Type 1 ◽  
Gastrointestinal Stromal Tumors ◽  
Neurofibromatosis Type ◽  
Stromal Tumors

Az 1-es típusú neurofibromatosis, más néven Recklinghausen-kór a leggyakoribb autoszomális dominánsan öröklődő betegségek egyike. A neurofibromatosis génje a 17-es kromoszómán található NF1 tumorszuppresszor gén. A gén mutációja a tumorszuppresszor funkció kiesése következtében benignus és malignus tumorok kialakulásához vezet. Gastrointestinalis manifesztáció az esetek 25%-ában észlelhető, a leggyakrabban GIST. Az irodalomban jól ismert a két betegség szoros asszociációja, jelenleg már több mint 160 esetről van tudomásunk. Neurofibromatosisos betegek 7%-ában alakul ki GIST, és a GIST-betegek között az NF1 előfordulása 150-180-szoros az átlagpopulációhoz képest. A neurofibromatosishoz társuló GIST külön entitás, a sporadikus GIST-től eltérően általában multiplex, és szinte mindig a vékonybélben fordul elő. Enyhe női túlsúllyal, általában fiatalabb korban jelenik meg. Szövettani jellemzői közül az orsósejtes típus, a skeinoid testek jelenléte és a gyakori S100-pozitivitás emelhető ki. Mitotikus aktivitása alacsony, általában a prognózisa is kedvezőbb. A sporadikus GIST-re jellemző c-KIT- és PDGFRA-mutáció igen ritkán fordul elő, azzal a hipotézissel összhangban, hogy a neurofibromatosishoz társuló GIST patogenezise nem c-KIT-függő. Feltételezik, hogy neurofibromatosisban a GIST patomechanizmusa különbözik a sporadikustól, a GIST-tumor megjelenése a neurofibromatosis klinikai spektrumának része. C-KIT- és PDGFRA-mutáció az ismert néhány esetben feltehetőleg a tumorgenezis késői lépéseként alakul ki. A GIST terápiáját forradalmasító imatinib ebben a betegcsoportban nem hatékony, de kellő mennyiségű adat még nem áll rendelkezésre.

Sign in / Sign up

Export Citation Format

Share Document